Akebia Therapeutics
Biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease. Core activities include discovery and development of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors and other renal-focused programs, execution of clinical trials through late stages, and commercialization and licensing of approved renal therapies.
Industries
Nr. of Employees
medium (51-250)
Akebia Therapeutics
Patents
Process for preparing [(3-hydroxypyridine-2-carbonyl)aminojalkanoic acids, esters and amides
US-12673919-B2
View DetailsTreatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer
US-12629357-B2
View DetailsMethod for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
US-12612367-B2
View Details
Process for preparing [(3-hydroxypyridine-2-carbonyl)aminojalkanoic acids, esters and amides
US-12673919-B2
View DetailsTreatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer
US-12629357-B2
View DetailsMethod for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
US-12612367-B2
View DetailsProducts
Oral HIF-PH inhibitor for anemia due to chronic kidney disease
An oral hypoxia-inducible factor prolyl hydroxylase inhibitor indicated for treatment of anemia associated with chronic kidney disease.
Oral ferric citrate for hyperphosphatemia and iron management
An oral ferric citrate product for control of serum phosphorus in patients with chronic kidney disease and for management of iron parameters.
Oral HIF-PH inhibitor for anemia due to chronic kidney disease
An oral hypoxia-inducible factor prolyl hydroxylase inhibitor indicated for treatment of anemia associated with chronic kidney disease.
Oral ferric citrate for hyperphosphatemia and iron management
An oral ferric citrate product for control of serum phosphorus in patients with chronic kidney disease and for management of iron parameters.
Services
Evaluation, licensing and co-development arrangements for commercial or late-stage renal and cardiorenal assets; business development contact provided for inquiries.
Evaluation, licensing and co-development arrangements for commercial or late-stage renal and cardiorenal assets; business development contact provided for inquiries.
Expertise Areas
- Nephrology drug development
- HIF pathway therapeutics
- Clinical trial management (Phase 1–3)
- Commercialization and market access for renal therapies
Key Technologies
- Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition
- sGC (soluble guanylate cyclase) stimulation
- Fusion-protein complement inhibition
- Oral small-molecule therapeutics
News & Updates
Public statement describing COVID-19 impacts on operations, clinical trials, remote monitoring practices, and supply chain considerations.
Public statement that the company has two products approved by the U.S. Food and Drug Administration for renal indications.
Partner received approval in Japan for a HIF-PH inhibitor for anemia due to CKD following a Japanese regulatory submission and approval process (approval obtained June 29, 2020 via partner).
Public statement describing COVID-19 impacts on operations, clinical trials, remote monitoring practices, and supply chain considerations.
Public statement that the company has two products approved by the U.S. Food and Drug Administration for renal indications.
Partner received approval in Japan for a HIF-PH inhibitor for anemia due to CKD following a Japanese regulatory submission and approval process (approval obtained June 29, 2020 via partner).